Engelskirchen, Germany
Engelskirchen, Germany

Biocell Center is an international company specializing in the cryopreservation and private banking of amniotic fluid stem cells. The company is headquartered in Italy with several international locations and is involved with numerous partnerships and research studies of amniotic fluid stem cells,.In 2008, Biocell Center opened the first amniotic fluid stem cell bank in the world, and in 2009 it opened the first amniotic fluid stem cell bank in the United States for private storage of stem cells obtained during genetic amniocentesisBiocell Center’s Italian headquarters in Busto Arsizio and Milan , are managed by company president Marco Reguzzoni and scientific director Giuseppe Simoni, and additional subsidiaries are located in Lugano , and Medford, Massachusetts - Boston area,Biocell Center is currently collaborating with several institutions, including Harvard University and the Caritas Christi Health Care hospital network , on several amniotic stem cell research projects. Wikipedia.


Time filter

Source Type

Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2007-1.1-2 | Award Amount: 5.00M | Year: 2008

Recent developments in the design and synthesis of nanoscale building blocks as active elements in opto- or bio-electronic devices with tailored electronic functionality have the potential to open up new horizons in nanoscience and also revolutionise multi-billion dollar markets across multiple technology sectors including healthcare, printable electronics, and security. Ligand-stabilised inorganic nanocrystals (~2-30 nm core diameters) and functional organic molecules are attractive building blocks due to their size dependent opto-electronic properties, the availability of low-cost synthesis processes and the potential for formation of ordered structures via (bio) molecular recognition and self-assembly. Harnessing the complementary properties of both nanocrystals and functional molecules thus represents a unique opportunity for generation of new knowledge and development of new classes of high knowledge-content materials with specific functionality tailored for key applications, e.g., printable electronics, biosensing or energy conversion in the medium term, and radically new information and signal processing paradigms in the long term. Self-assembly and self-organisation processes offer the potential to achieve dimensional control of novel multifunctional materials at length scales not accessible to conventional top-down technologies based on lithography. It is critical for European industry to develop new knowledge and low-cost, scaleable processes for assembly and electrical interfacing of these multifunctional materials with conventional contact electrodes in order to produce into tailored devices and products, in particular on low-cost substrates. The FUNMOL consortium will deliver substantial innovation to European industry via development of cost-effective, scaleable processes for directed assembly of high-knowledge content nanocrystal-molecule materials into electrically-interfaced devices at silicon oxide, glass and plastic substrates.


News Article | December 7, 2015
Site: phys.org

Biocell attached to CMOS integrated circuit with membrane containing sodium-potassium pumps in pore. Credit: Trevor Finney and Jared Roseman/Columbia Engineering Columbia Engineering researchers have, for the first time, harnessed the molecular machinery of living systems to power an integrated circuit from adenosine triphosphate (ATP), the energy currency of life. They achieved this by integrating a conventional solid-state complementary metal-oxide-semiconductor (CMOS) integrated circuit with an artificial lipid bilayer membrane containing ATP-powered ion pumps, opening the door to creating entirely new artificial systems that contain both biological and solid-state components. The study, led by Ken Shepard, Lau Family Professor of Electrical Engineering and professor of biomedical engineering at Columbia Engineering, is published online Dec. 7 in Nature Communications. "In combining a biological electronic device with CMOS, we will be able to create new systems not possible with either technology alone," says Shepard. "We are excited at the prospect of expanding the palette of active devices that will have new functions, such as harvesting energy from ATP, as was done here, or recognizing specific molecules, giving chips the potential to taste and smell. This was quite a unique new direction for us and it has great potential to give solid-state systems new capabilities with biological components." Shepard, whose lab is a leader in the development of engineered solid-state systems interfaced to biological systems, notes that despite its overwhelming success, CMOS solid-state electronics is incapable of replicating certain functions natural to living systems, such as the senses of taste and smell and the use of biochemical energy sources. Living systems achieve this functionality with their own version of electronics based on lipid membranes and ion channels and pumps, which act as a kind of 'biological transistor.' They use charge in the form of ions to carry energy and information—ion channels control the flow of ions across cell membranes. Solid-state systems, such as those in computers and communication devices, use electrons; their electronic signaling and power are controlled by field-effect transistors. In living systems, energy is stored in potentials across lipid membranes, in this case created through the action of ion pumps. ATP is used to transport energy from where it is generated to where it is consumed in the cell. To build a prototype of their hybrid system, Shepard's team, led by PhD student Jared Roseman, packaged a CMOS integrated circuit (IC) with an ATP-harvesting 'biocell.' In the presence of ATP, the system pumped ions across the membrane, producing an electrical potential harvested by the IC. "We made a macroscale version of this system, at the scale of several millimeters, to see if it worked," Shepard notes. "Our results provide new insight into a generalized circuit model, enabling us to determine the conditions to maximize the efficiency of harnessing chemical energy through the action of these ion pumps. We will now be looking at how to scale the system down." While other groups have harvested energy from living systems, Shepard and his team are exploring how to do this at the molecular level, isolating just the desired function and interfacing this with electronics. "We don't need the whole cell," he explains. "We just grab the component of the cell that's doing what we want. For this project, we isolated the ATPases because they were the proteins that allowed us to extract energy from ATP." The ability to build a system that combines the power of solid-state electronics with the capabilities of biological components has great promise. "You need a bomb-sniffing dog now, but if you can take just the part of the dog that is useful—the molecules that are doing the sensing—we wouldn't need the whole animal," says Shepard. "With appropriate scaling, this technology could provide a power source for implanted systems in ATP-rich environments such as inside living cells," added Roseman. Explore further: Nanotube transistor controlled by ATP could improve man-machine communication


News Article | November 2, 2016
Site: www.marketwired.com

SEATTLE, WA--(Marketwired - Nov 2, 2016) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals ( : ATTBF) ( : ATT). The company recently announced the receipt of a Controlled Substance License from Health Canada for Northern Vine Laboratories, a company in which Abattis has a 75% stake. The Northern Vine lab site is built, security is in place, and all of the government inspections are complete. Once the lab's equipment is properly calibrated, Northern Vine will be open for business. Initially, Northern Vine will be providing independent, neutral testing services to Licensed Producers as well as to individuals using medical marijuana under the current regulations. This will be the primary revenue source, and market indications show no shortage of demand for the services. Located in Langley, BC, Northern Vines is in the heart of the Vancouver-area market and will be one of the only testing facilities on the Lower Mainland. Along with the safety testing services, Northern Vine can act as an incubator for product formulations and Intellectual Property development, either contractually for outside companies or for Abattis itself. Northern Vine's long-anticipated federal license has moved the company from the hypothetical world into the real one. Combined with Abattis' ownership of its LP application in Quebec called Biocell Labs Inc., and its announcement of an agreement to acquire up to 100% of Experion Biotechnologies Inc., a Licensed Producer applicant in the Vancouver area, these developments reflect a comprehensive long-term plan. If any of the current or future LP applications go through, Abattis will have a production and distribution operation to complement Northern Vine's testing and product development capabilities. Abattis' other established business, Vergence Sales and Marketing, already offers bioceutical products to consumers. With distribution in place and the groundwork being laid for additional Asian channels, Vergence completes the full circle of Abattis' plan to become a full service legal cannabis operation. From seed to sale, Abattis is putting together a comprehensive business right before our eyes. Click here to read the full article: http://www.cannabisfn.com/abattis-federally-licensed-lab-and-the-crucial-role-it-plays/ Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/ Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8 Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed. Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.


Schwartz S.R.,International Research Services Inc | Park J.,Biocell
Clinical Interventions in Aging | Year: 2012

Skin aging and its clinical manifestation is associated with altered molecular metabolism in the extracellular matrix of the dermis. In a pilot open-label study, we investigated the effect of a dietary supplement, BioCell Collagen® (BCC), which contains a naturally occurring matrix of hydrolyzed collagen type II and low-molecular-weight hyaluronic acid and chondroitin sulfate, in 26 healthy females who displayed visible signs of natural and photoaging in the face. Daily supplementation with 1 g of BCC for 12 weeks led to a significant reduction of skin dryness/scaling (76%, P = 0.002) and global lines/wrinkles (13.2%, P = 0.028) as measured by visual/tactile score. Additionally, a significant increase in the content of hemoglobin (17.7%, P = 0.018) and collagen (6.3%, P = 0.002) in the skin dermis was observed after 6 weeks of supplementation. At the end of the study, the increase in hemoglobin remained significant (15%, P = 0.008), while the increase in collagen content was maintained, but the difference from baseline was not significant (3.5%, P = 0.134). This study provides preliminary data suggesting that dietary supplementation with BCC elicits several physiological events which can be harnessed to counteract natural photoaging processes to reduce visible aging signs in the human face. A controlled study is necessary to verify these observations. © 2012 Schwartz and Park, publisher and licensee Dove Medical Press Ltd.


Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are administered through a topical delivery medium for absorption into a dermis of the individual.


A method of collection, classification and conservation of stem cells comprises the following steps: taking a sample of organic material by continuously maintaining a total microbiological, atmospheric and physical isolation between a sampling volume, the sample and a collection portion w herein the sample is confined, manipulating said sample under sterility conditions by an isolator apparatus, for determining a presence and/or an amount and/or developing capabilities of stem cells trapped in said sample and preserving the sample; the steps of taking the sample, manipulating the sample and preserving the sample are performed on a sample comprising at least a portion of organic tissue wherein stem cells are trapped in and are also performed on the sample in its entirety, without separating the stem cells from the portion of organic tissue.


An improved isolator for collection, parametrical characterization and long-term preservation of samples containing stem cells comprises: a work chamber (2) isolated from the external environment; gloves jutting out at an inside of said work chamber (2); an inlet chamber (4) for introduction of a sample to be processed; an outlet chamber connected with the work chamber (2) and having a sterile sample-collecting bag; sterilizing means acting on said sample and/or on said inside of the work chamber (2); filtering means; cooling means for bringing and keeping said sample at a constant working temperature throughout the inlet chamber (4), the work chamber (2) and the outlet chamber; and visual imaging means (5) focused on the sample and defining a visual path which maintains a complete mechanical and pneumatic/hydraulic isolation between said inside of the work chamber (2) and the external environment.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Innovation Voucher | Award Amount: 5.00K | Year: 2015

Lancaster University Lancaster Environment Centre Lancaster LA1 4YG


A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.


A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.

Loading Biocell collaborators
Loading Biocell collaborators